Efficacy and Safety of Brolucizumab was more than Aflibercep
A Study was conducted to compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study.

Of the Japanese participants with PCV, 39 received brolucizumab 6mg and 30 received aflibercept 2mg. After 3monthly loading doses, brolucizumab-treated eyes received an injection every 12 weeks (q12w) but were adjusted to q8w if disease activity was detected. Aflibercept-treated eyes received fixed q8w dosing. Mean change in best-corrected visual acuity (BCVA), the proportion of participants on q12w, retinal thickness, retinal fluid changes and safety were assessed to Week 96.

--Mean change in BCVA (early treatment diabetic retinopathy study (ETDRS) letters) from baseline to week 48/week 96 was+10.4/+11.4 for brolucizumab and +11.6/+11.1 for aflibercept.

--For brolucizumab-treated eyes, the probability of only q12w dosing after loading through week 48 was 76%, and 68% through week 96.

--Fluid resolution was greater with brolucizumab than aflibercept: respective proportions of eyes with intraretinal fluid and/or subretinal fluid were 7.7% and 30% at week 48% and 12.8% and 16.7% at week 96.

--Brolucizumab exhibited an overall well-tolerated safety profile despite a higher rate of intraocular inflammation compared with aflibercept.

Brolucizumab monotherapy q12w/qu8w resulted in substantial, consistent BCVA improvements comparable to q8w aflibercept dose in Japanese eyes with PCV. Brolucizumab has benefited from anatomical results over aflibercept, with 76% of brolucizumab subjects sustained a q12w dose following loading at week 48.

Source: https://bjo.bmj.com/content/early/2021/07/22/bjophthalmol-2021-319090?rss=1